878025-42-4

Basic information

• Product Name: N-Methyl-5,6,7,8-tetrahydroquinolin-8-aMine
• Synonyms: N-Methyl-5,6,7,8-tetrahydroquinolin-8-aMine;5,6,7,8-tetrahydro-N-methyl-8-Quinolinamine;Methyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine
• CAS NO: 878025-42-4
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.23156
• Mol File: 878025-42-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-Methyl-5,6,7,8-tetrahydroquinolin-8-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methyl-5,6,7,8-tetrahydroquinolin-8-aMine(878025-42-4)
• EPA Substance Registry System: N-Methyl-5,6,7,8-tetrahydroquinolin-8-aMine(878025-42-4)

Safety Data

• Hazardous Substances Data: 878025-42-4(Hazardous Substances Data)

Upstream product

• 56826-69-8 5,6,7,8-tetrahydro-8-quinolinone 
• 74-89-5 methylamine 
• 10500-57-9 5,6,7,8-tetrahydroquinoline 
• 106057-23-2 8-chloro-5,6,7,8-tetrahydroquinoline 

Downstream Products

• 1189532-56-6 1-phenyl-1H-1,2,3-triazole-4-carbaldehyde 

Relevant articles and documents

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

The important roles of the CXCL12/CXCR4 axis in numerous pathogenic pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced cytosolic calcium increase (IC50 = 2.3 nM). Furthermore, compound 3 possesses good physicochemical properties (MW 353, clogP 2.0, PSA 48, pKa 6.7) and exhibits minimal hERG and CYP isozyme (e.g. 3A4, 2D6) inhibition. Collectively, these results strongly support further optimization of this novel scaffold to develop better CXCR4 antagonists.

Multi-substituted amine compound and its preparation and use (by machine translation)

The invention belongs to the field of medical technology, in particular, the present invention provides the following formula I shown multi-substituted amine compound or its isomer or its pharmaceutically acceptable salt, ester, prodrug or hydrate, its pharmaceutical composition, preparation method thereof and its use in the preparation of medicine for treating aids in use. The compound or pharmaceutical composition containing the compound can be used as an inhibitor for inhibiting HIV integrase with LEDGF/p75 between protein - protein interaction and HIV integrase dimerization, then can be used for the treatment of aids. . (by machine translation)

CHEMICAL COMPOUNDS

The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a recep